A Phase 2 Multicenter, Randomized, Double-Blind, Placebo-Controlled, 3-Period Crossover Study to Evaluate the Efficacy and Safety of Recombinant Human C1 Inhibitor in the Prophylaxis of Angioedema Attacks in Patients With Hereditary Angioedema (HAE)

Trial Profile

A Phase 2 Multicenter, Randomized, Double-Blind, Placebo-Controlled, 3-Period Crossover Study to Evaluate the Efficacy and Safety of Recombinant Human C1 Inhibitor in the Prophylaxis of Angioedema Attacks in Patients With Hereditary Angioedema (HAE)

Completed
Phase of Trial: Phase II

Latest Information Update: 16 Jan 2018

At a glance

  • Drugs Conestat alfa (Primary)
  • Indications Hereditary angioedema
  • Focus Registrational; Therapeutic Use
  • Sponsors Pharming Group NV
  • Most Recent Events

    • 16 Jan 2018 According to a Pharming Group media release, based on the data from this and another trial (CT profile 700248808), the U.S. Food and Drug Administration (FDA) has accepted for review supplemental Biologics License Application (sBLA) for RUCONEST [Recombinant Human C1 Esterase Inhibitor/ conestat alfa] for routine prophylaxis to prevent attacks in adult and adolescent patients with hereditary angioedema (HAE). The FDA has set an action date of September 21, 2018.
    • 27 Nov 2017 According to a Pharming NV media release, based on the data from this and another trial (CT profile 700248808), the company has submitted a supplemental Biologics License Application (BLA) to the US FDA for RUCONEST (Recombinant Human C1 Esterase Inhibitor/conestat alfa) for routine prophylaxis to prevent attacks in adult and adolescent patients with hereditary angioedema.
    • 11 Sep 2017 According to a Pharming Group media release, base on the data from this and OPERA study, company will submit a BLA efficacy supplement (sBLA) to include routine prophylaxis against angioedema attacks in adolescent and adult patients with Hereditary Angioedema (HAE) as an expanded indication for RUCONEST (Conestat-alfa) in Q4 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top